New hope for lymphoma patients: experimental drug glofitamab shows promise in early trial
NCT ID NCT03075696
First seen Nov 01, 2025 · Last updated May 25, 2026 · Updated 30 times
Summary
This study is testing a new drug called glofitamab, alone or with another drug (obinutuzumab), in about 940 people whose B-cell non-Hodgkin's lymphoma has come back or stopped responding to standard treatments. The goal is to find the safest and most effective dose and see how well it shrinks tumors. Participants receive the drugs through an IV, and the study is still ongoing but no longer recruiting new patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-HODGKIN'S LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
AUSL della Romagna
Ravenna, Emilia-Romagna, 48121, Italy
-
Allegheny Health Network (Pittsburg PA)
Pittsburgh, Pennsylvania, 15212, United States
-
Auckland Cancer Trial Centre
Auckland, 1023, New Zealand
-
CHU DE RENNES - CHU Pontchaillou
Rennes, 35033, France
-
CHU Saint Eloi
Montpellier, 34295, France
-
Ch Lyon Sud
Pierre-Bénite, 69495, France
-
China Medical University Hospital
Taichung, 404, Taiwan
-
Cliniques Universitaires St-Luc
Brussels, 1200, Belgium
-
Fond. IRCCS Istituto Nazionale Tumori
Milan, Lombardy, 20133, Italy
-
Helsinki University Central Hospital
Helsinki, 00029, Finland
-
Hopital Claude Huriez
Lille, 59037, France
-
Hopital Henri Mondor
Créteil, 94010, France
-
Hospital Duran i Reynals L'Hospitalet
L'Hospitalet de Llobregat, Barcelona, 08908, Spain
-
Hospital Univ. 12 de Octubre
Madrid, 28041, Spain
-
Hospital Universitari Germans Trias i Pujol
Badalona, Barcelona, 08915, Spain
-
Hospital Universitari Vall d'Hebron
Barcelona, 08035, Spain
-
Hospital Universitario Marques de Valdecilla
Santander, Cantabria, 39008, Spain
-
Hospital del Mar
Barcelona, 08003, Spain
-
Istituto Clinico Humanitas
Rozzano, Lombardy, 20089, Italy
-
MSKCC
New York, New York, 10065, United States
-
Mount Sinai Medical Center
New York, New York, 10029, United States
-
National Taiwan Universtiy Hospital
Taipei, 100, Taiwan
-
Peter Maccallum Cancer Centre
Melbourne, Victoria, 3000, Australia
-
Prince of Wales Hospital
Randwick, New South Wales, 2031, Australia
-
Princess Margaret Cancer Center
Toronto, Ontario, M5G 1Z5, Canada
-
Rigshospitalet
København Ø, 2100, Denmark
-
Swedish Cancer Inst.
Seattle, Washington, 98104, United States
-
UZ Gent
Ghent, 9000, Belgium
-
University of Michigan
Ann Arbor, Michigan, 48109-0934, United States
-
Uniwersytecki Szpital Kliniczny im. Jana Mikulicza-Radeckiego we Wroclawiu
Wroc?aw, 50-367, Poland
-
Uniwersytecki Szpital Kliniczny w Poznaniu
Późna, 60-569, Poland
-
Uniwersyteckie Centrum Kliniczne
Gda?sk, 80-214, Poland
-
Vseobecna Fakultni Nemocnice v Praze, I. Interni Klinika - Klinika Hematoonkologie VFN a 1. LF UK
Prague, 128 08, Czechia
-
Washington University
St Louis, Missouri, 63110, United States
Conditions
Explore the condition pages connected to this study.